Curative Therapies Grant
Curative Therapies Grant supports scientists worldwide researching curative and disease-modifying therapies for Fragile X syndrome, with the goal of bringing practical treatments into medical practice.
Browse similar grants
Funder: FRAXA Research Foundation
Due Dates: Rolling (Curative Therapies) | February 1, 2027 (Separate fellowship route)
Funding Amounts: Up to $100,000 per year; no timeframe limit, with yearly renewal for multiyear grants
Summary: Supports research directed specifically at developing curative and disease-modifying therapies for Fragile X syndrome.
Key Information: Institutions must waive indirect costs, and applicants must submit a Letter of Intent and discuss proposals with FRAXA’s Chief Scientific Officer before applying.
Description
FRAXA Research Foundation’s Curative Therapies Grant accelerates the development of treatments and ultimately a cure for Fragile X syndrome. The program supports disease-modifying approaches grounded in Fragile X disease mechanisms, including gene therapy, gene repair, gene reactivation, protein replacement, mRNA therapeutics, and targeted ASO treatments. Research may also address enhanced model systems, biomarkers, and specific therapeutic development, provided all work is directed specifically at Fragile X therapeutics.
FRAXA funds scientists worldwide and prioritizes projects with clear practical applications whose results will be shared promptly. Its goal is to bring practical treatments into medical practice as quickly as possible. The foundation continually reassesses research priorities to remove bottlenecks in treatment development; basic disease-mechanism research is now a lower priority, while clinical trials are a high priority.
